Product image of Mycolat (Mycophenolate Mofetil) supplied by GNH India

Mycolat

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycolat (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycolat, is an antimetabolite presented as an oral formulation for oral use. It suppresses the immune system to help prevent organ transplant rejection and is sometimes employed off‑label for certain autoimmune disorders.

GNH India supplies Mycolat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to European Union quality standards, provides regulatory‑approved batches for global distribution, and offers reliable logistics, batch traceability, and dedicated technical support.

Manufacturer / TM Owner

Rowex Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mycolat (mycophenolate mofetil) is used in immunosuppressive therapy to reduce lymphocyte‑mediated rejection.
  • Organ transplant rejection: prevents acute and chronic graft rejection by inhibiting lymphocyte proliferation.
  • Kidney transplantation: lowers the incidence of rejection episodes in renal graft recipients.
  • Autoimmune diseases (off‑label): may be employed to control severe lupus, vasculitis, or other immune‑mediated conditions when standard therapies are insufficient.

How It Works

  • Mycophenolate mofetil selectively inhibits inosine monophosphate dehydrogenase, an enzyme essential for de novo guanosine nucleotide synthesis. By blocking this pathway, the drug reduces guanosine pools in lymphocytes, leading to impaired DNA replication and suppressed proliferation of T and B cells, thereby dampening the immune response that drives graft rejection and autoimmune activity.

Side Effects

Mycolat may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea or vomiting
  • Diarrhea or abdominal discomfort
  • Headache
  • Mild infections such as upper respiratory tract infections
  • Anemia or leukopenia
  • Elevated liver enzymes

Serious or Rare Side Effects

  • Severe or opportunistic infections (e.g., cytomegalovirus, fungal infections)
  • Malignancies, including lymphoproliferative disorders
  • Progressive multifocal leukoencephalopathy (PML)
  • Significant bone marrow suppression leading to pancytopenia
  • Hepatic failure or severe hepatitis

Precautions & Warnings

Before initiating Mycolat, clinicians should assess baseline laboratory values and patient risk factors.

  • Blood monitoring: perform regular complete blood counts and renal function tests.
  • Infection risk: monitor for signs of bacterial, viral, or fungal infections.
  • Pregnancy: contraindicated; avoid use in women who are pregnant or may become pregnant.
  • Live vaccines: do not administer live attenuated vaccines while on therapy.
  • Drug interactions: review concomitant medications for potential interactions, especially with azathioprine or strong CYP3A4 inhibitors.
  • Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Mycolat can interact with several medicines, requiring careful review.

Major Interactions (Avoid)

  • Azathioprine: combined use markedly increases bone‑marrow toxicity.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise mycophenolate levels and risk of severe adverse events.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours.
  • Warfarin: may enhance anticoagulant effect; monitor INR closely.
  • Vaccines (non‑live): efficacy may be reduced; assess immune response when needed.

Frequently Asked Questions

Mycolat contains mycophenolate mofetil, an immunosuppressive agent used primarily to prevent acute and chronic rejection in organ transplant recipients. It may also be prescribed off‑label for severe autoimmune conditions when conventional therapies are inadequate.

Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase, which is critical for de novo synthesis of guanosine nucleotides. This blockade reduces the proliferation of T and B lymphocytes, thereby dampening the immune response that can damage transplanted organs or drive autoimmune disease.

The dosage of Mycolat is individualized by the prescribing physician based on the type of transplant, patient weight, renal function, and concomitant immunosuppressive therapy. No standard dose is provided here; the prescriber will set the appropriate regimen.

Mycolat is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as the drug passes into milk and may affect the infant.

To order Mycolat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Compared with azathioprine, mycophenolate mofetil offers more selective inhibition of lymphocyte proliferation and often a lower incidence of certain toxicities, but it may carry a higher risk of gastrointestinal upset. Unlike calcineurin inhibitors such as tacrolimus, it does not cause nephrotoxicity, making it a useful component of combination regimens.

Mycolat should be stored at ambient temperature below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Mycolat is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a full glass of water; they should not be crushed, chewed, or split unless specifically instructed.

The most serious risks include severe infections (bacterial, viral, fungal), opportunistic infections such as cytomegalovirus or PML, bone‑marrow suppression leading to pancytopenia, and an increased long‑term risk of certain malignancies. Patients should be monitored closely for these complications.

Mycolat should not be used by pregnant women, individuals with uncontrolled severe infections, patients with known hypersensitivity to mycophenolate mofetil or any excipients, and those with severe hepatic impairment unless the prescriber determines the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT